Contemporary Management of HIV: Therapies and Strategies in Advanced Clinical Development
Slideset - In this downloadable slideset, Paul E. Sax, MD, and Program Director Joseph J. Eron, Jr., MD, review key data on emerging investigational agents and strategies. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - April 6, 2017 Category: Infectious Diseases Source Type: research
My Take on CROI Data Evaluating CNS Effects With INSTIs
Discussion - Recent data highlighting the potential for CNS effects with newer INSTIs has given me a sense of d éjà vu about how we once approached the same issue with efavirenz. Here’s my take on what we know and how to proceed. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - April 5, 2017 Category: Infectious Diseases Source Type: research
Hepatitis C Management for the HIV Provider
Slideset - In this downloadable slideset, Kristen Marks, MD, reviews important management issues to consider when treating HCV in patients coinfected with HIV. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - March 29, 2017 Category: Infectious Diseases Source Type: research
Top Advances in ART for 2017
Slideset - In this downloadable slideset, Joel E. Gallant, MD, MPH, provides a comprehensive update on ART management. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - March 29, 2017 Category: Infectious Diseases Source Type: research
Key Studies Influencing My Practice Following CROI 2017
Audio - Listen to this downloadable audio from a live Webinar in which an expert faculty member discusses the clinical impact of new data reported at the Seattle meeting. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - March 3, 2017 Category: Infectious Diseases Source Type: research
Clinical Impact of New Data From CROI 2017
Slideset - Expert faculty members Joel E. Gallant, MD, MPH, and Charles B. Hicks, MD, summarize key studies from this important annual conference. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - March 3, 2017 Category: Infectious Diseases Source Type: research
Novel INSTI Bictegravir Plus TAF/FTC Demonstrates Efficacy, Safety in ART-Naive Patients in Phase II Trial
Conference Capsule - Efficacy and safety of bictegravir plus TAF/FTC comparable to that of DTG plus TAF/FTC. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - February 23, 2017 Category: Infectious Diseases Source Type: research
HPTN 076: Injectable Form of Rilpivirine (TMC278 LA) Safe, Tolerable, and Acceptable as Long-Acting HIV Pre-Exposure Prophylaxis
Conference Capsule - After receiving TMC278 LA injections, 68% of participants strongly agreed they would use an injectable prophylaxis in the future. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - February 23, 2017 Category: Infectious Diseases Source Type: research
Studies 104/111: TAF-Based Regimen Superior to TDF Through 144 Weeks in Treatment-Naive Patients
Conference Capsule - EVG/COBI/FTC/TAF continued to be associated with improvements in renal and bone markers vs EVG/COBI/FTC/TDF through 144 weeks. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - February 23, 2017 Category: Infectious Diseases Source Type: research
ANRS 167 LAMIDOL: Switch to Dual Therapy With Dolutegravir Plus Lamivudine Effective in Maintaining Virologic Suppression
Conference Capsule - 97% of patients maintained virologic suppression following switch from initial triple-therapy ART to dolutegravir plus lamivudine with a low incidence of serious adverse events. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - February 22, 2017 Category: Infectious Diseases Source Type: research
DAHHS: Decreased Incidence of Acute HCV in Dutch HIV-Positive MSM Following Unrestricted HCV Direct-Acting Antiviral Availability
Conference Capsule - Although acute HCV incidence declined by 51%, syphilis diagnoses increased by 41% in Dutch public health STD clinics between 2015 and 2016. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - February 22, 2017 Category: Infectious Diseases Source Type: research
GS-109/112: Switch From TDF- to TAF-Based ART Improves Bone Mineral Density in HIV-Infected Patients With Low Baseline Bone Mineral Density
Conference Capsule - High bone turnover and urinary phosphate wasting could identify patients most likely to benefit from TDF to TAF switch. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - February 21, 2017 Category: Infectious Diseases Source Type: research
BCN02-Romi: Lasting Viral Control With Conserved HIV Vaccines Plus Viral Reactivating Agent Romidepsin in HIV-Infected Patients Treated With Early ART
Conference Capsule - The combination drove a strong immune response and detectable viremia with no additional toxicity compared with vaccines alone. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - February 19, 2017 Category: Infectious Diseases Source Type: research
Novel NNRTI Elsulfavirine (VM1500) Plus TDF/FTC Demonstrates Efficacy, Safety in ART-Naive Patients in Phase IIb Trial
Conference Capsule - Efficacy of elsulfavirine plus TDF/FTC comparable to that of EFV plus TDF/FTC but with lower frequency of drug-related AEs and specific CNS events. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - February 19, 2017 Category: Infectious Diseases Source Type: research
D:A:D: Cumulative Use of Darunavir/Ritonavir Associated With Increased CVD Risk
Conference Capsule - Follow-up observational study detects small yet significant CVD risk with 5-year cumulative use of darunavir/ritonavir but no risk with atazanavir/ritonavir. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - February 19, 2017 Category: Infectious Diseases Source Type: research
